Engine Biosciences is a technology-enabled drug discovery company that leverages its proprietary platform to discover and develop new therapeutics. The company integrates biology and technology to map disease circuitry and identify potential drug candidates more efficiently.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies.  We are actively applying the platform internally and with partners across a range of disease indications.

In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Polaris Partners

EDBI

Seeds Capital

ClavystBio

Invus

Coronet Ventures

WI Harper Group

6 Dimensions Capital

Baidu Ventures

Vectr

Nest.Bio Ventures

Goodman Capital

DHVC

Engine Biosciences

Engine Bio is honored to be recognised by Singapore Minister of Trade and Industry Gan Kim Yong for our work to pioneer Al-enabled therapeutics and biomarkers for precision medicine. We are very encouraged by our progress and strong supporters, and we are motivated to keep pushing to deliver impact in healthcare and pharmaceuticals!

(See 13:40 for Minister Gan’s remarks on Engine Bio):

Jeffrey Lu, CEO and co-founder of precision medicines company Engine Biosciences, foresaw "accelerating adoption of Al in biopharma R&D across the value chain. Not only has the 2023 Al boom opened the world's eyes dramatically, application-specific tools that have been built rigorously over the past several years in uses cases like small-molecule screening, target selection, protein design, and patient stratification are reaching greater maturity in technology validation and operational deployment."

Thank you Minister Gan Kim Yong and Ministry of Trade and Industry (Singapore)  for giving us the privilege of hosting you and your colleagues from Enterprise Singapore  and Singapore Economic Development Board (EDB) at our Silicon Valley office!  We enjoyed discussing the opportunities around #precisionmedicine, and Engine Biosciences’ approach by identifying targets, drugs, and biomarkers coming out of our R&D efforts in both Singapore and California.

COM:ENGINEBIO

Engine Biosciences

Analysis Not Available